Quebec Expands Patient Access to Chronic Hepatitis C Therapies

Gilead applauds Quebec's Ministry of Health for expanding access to curative hepatitis C therapies to all diagnosed patients, regardless of severity of illness Quebec's expanded access includes EPCLUSA®, a 12 week treatment for patients with chronic hepatitis C across all six genotypes Gilead's new product, VOSEVI™ is now available on the List of Medications The removal of the fibrosis level criterion for access furthers Canada's co...

ZEPATIER® now covered in Quebec for the treatment of chronic hepatitis C

KIRKLAND, QC, March 21, 2017 /CNW Telbec/ - Merck Canada Inc. today announced that ZEPATIER® (elbasvir/grazoprevir) will be listed among the drugs covered by Quebec's health insurance board, the Régie de l'assurance maladie du Québec (RAMQ), as of March 22. Quebec joins other jurisdictions that have approved the product for reimbursement under their public healthcare plans for chronic hepatitis C patients presenting with recognized criteria. Zepatier is i

EPCLUSA™, to treat all six genotypes of chronic hepatitis C infection, added to the Liste des médicaments de la RAMQ (Quebec)

-- Quebec Broadens Access for Patients with Less Advanced Disease Who Have Other Health Conditions -- MISSISSAUGA, ON, March 20, 2017 /CNW/ - Gilead Sciences Canada, Inc. (Gilead Canada) commends the continued leadership of Quebec in the treatment of hepatitis C with the listing of EPCLUSA™ (sofosbuvir/velpatasvir) tablets effective on March 22, 2017.  EPCLUSA is the first once-daily, pan-genotypic single tablet regimen for the treatment of adults with g...

Summer of Interferon-free Hepatitis C Drug Approvals?

2015 is stacking up to have a Summer of Interferon-Free hepatitis C drug approvals! So far we've had the following approvals for provincial Pharmacare coverage (addition to provincial "formulary"):On June 29th, Ontario covered AbbVie's Holkira Pak™ for genotype 1, on July 24th, Quebec covered both Gilead's Harvoni™ and AbbVie's Holkira Pak™ for genotype 1. And on World Hepatitis Day, July 28th British Columbia, Saskatchewan, Manitoba, and Yukon started to ...

Updated: HARVONI & SOVALDI now covered by BC PHARMACARE!!

HARVONI and SOVALDI ACCESS in CANADA, UPDATES as of March 26 (for original Press Release scroll to page bottom) British Columbia UPDATE on SOVALDI/HARVONI TREATMENT CRITERA and ACCESS as of March 26: BC PharmaCare Listing Criteria: BC PharmaCare Information for Prescribers – Sofosbuvir-ledipasvir (Harvoni™) for the treatment of chronic hepatitis C infection g

Simeprevir (GALEXOS) now covered in Quebec as well!

Simeprevir (GALEXOS) is also now covered on the Quebec formulary, according to CATIE, the Canadian AIDS Treatment Information Exchange. However, it is only available to those who have already failed conventional treatment with interferon and ribavirin. It is available only to genotype 1 patients who do not have the Q80K mutation and not co-infected with HIV. MUST MEET ALL THESE QUALIFICATIONS TO GET REIMBURSED FOR SIMEPREVIR: -- to be used in association w

QUEBEC approves SOVALDI for Hepatitis C (genotypes 1 or 4 only)

Great news from our friends at CAPAHC in Quebec! Their pharmacare (Régie de l'assurance maladie du Québec) has approved coverage for sofosbuvir (SOVALDI) for hepatitis C, genotypes 1 or 4, without requiring patients to provide proof of significant organ damage.  Read more here: and here as well: